Suppression of adenosine 2a receptor (A2aR)-mediated adenosine signaling improves disease phenotypes in a mouse model of amyotrophic lateral sclerosis

Experimental Neurology

Volumn 267, Issue , 2015, Pages 115-122

  Ng, Seng kah ^a   Higashimori, Haruki ^a   Tolman, Michaela ^a,b   Yang, Yongjie ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

A2a receptor; Adenosine; Amyotrophic lateral sclerosis (ALS); Astrocyte; KW6002; Motor neuron

Indexed keywords

ADENOSINE; ADENOSINE 1 RECEPTOR; ADENOSINE 2A RECEPTOR; ADENOSINE RECEPTOR; UNCLASSIFIED DRUG; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; ISTRADEFYLLINE; MEDIATOR COMPLEX; PURINE DERIVATIVE; SOD1 G93A PROTEIN; SUPEROXIDE DISMUTASE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EMBRYO; EMBRYONIC STEM CELL; FEMALE; GENE REPRESSION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MIDDLE AGED; MOUSE; NERVE CELL NECROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; SPINAL CORD MOTONEURON; VERY ELDERLY; ANIMAL; ASTROCYTE; BRAIN CORTEX; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; MOTONEURON; MUSCLE STRENGTH; PATHOLOGY; PHYSIOLOGY; SPINAL CORD; TRANSGENIC MOUSE;

ADENOSINE; ADENOSINE A2 RECEPTOR ANTAGONISTS; AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ASTROCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MEDIATOR COMPLEX; MICE; MICE, TRANSGENIC; MIDDLE AGED; MOTOR NEURONS; MUSCLE STRENGTH; PURINES; RECEPTOR, ADENOSINE A2A; SIGNAL TRANSDUCTION; SPINAL CORD; SUPEROXIDE DISMUTASE;

EID: 84924956494     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2015.03.004     Document Type: Article

References (44)

1. Aoyama S., Kase H., Borrelli E. Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J. Neurosci. 2000, 20:5848-5852.
2. Armentero M.T., Pinna A., Ferre S., Lanciego J.L., Muller C.E., Franco R. Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol. Ther. 2011, 132:280-299.
3. Azevedo F.A., Carvalho L.R., Grinberg L.T., Farfel J.M., Ferretti R.E., Leite R.E., Jacob Filho W., Lent R., Herculano-Houzel S. Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. J. Comp. Neurol. 2009, 513:532-541.
4. Bairam A., Joseph V., Lajeunesse Y., Kinkead R. Altered expression of adenosine A1 and A2A receptors in the carotid body and nucleus tractus solitarius of adult male and female rats following neonatal caffeine treatment. Brain Res. 2009, 1287:74-83.
5. Blutstein T., Haydon P.G. The importance of astrocyte-derived purines in the modulation of sleep. Glia 2013, 61:129-139.
6. Boillee S., Yamanaka K., Lobsiger C.S., Copeland N.G., Jenkins N.A., Kassiotis G., Kollias G., Cleveland D.W. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006, 312:1389-1392.
7. Boison D., Chen J.F., Fredholm B.B. Adenosine signaling and function in glial cells. Cell Death Differ. 2010, 17:1071-1082.
8. Bruijn L.I., Houseweart M.K., Kato S., Anderson K.L., Anderson S.D., Ohama E., Reaume A.G., Scott R.W., Cleveland D.W. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998, 281:1851-1854.
9. Brundege J.M., Dunwiddie T.V. Role of adenosine as a modulator of synaptic activity in the central nervous system. Adv. Pharmacol. 1997, 39:353-391.
10. Burnstock G. The past, present and future of purine nucleotides as signalling molecules. Neuropharmacology 1997, 36:1127-1139.
11. Cahoy J.D., Emery B., Kaushal A., Foo L.C., Zamanian J.L., Christopherson K.S., Xing Y., Lubischer J.L., Krieg P.A., Krupenko S.A., Thompson W.J., Barres B.A. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J. Neurosci. 2008, 28:264-278.
12. Chen J.F., Huang Z., Ma J., Zhu J., Moratalla R., Standaert D., Moskowitz M.A., Fink J.S., Schwarzschild M.A. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci. 1999, 19:9192-9200.
13. Choca J.I., Proudfit H.K., Green R.D. Identification of A1 and A2 adenosine receptors in the rat spinal cord. J. Pharmacol. Exp. Ther. 1987, 242:905-910.
14. Clement A.M., Nguyen M.D., Roberts E.A., Garcia M.L., Boillee S., Rule M., McMahon A.P., Doucette W., Siwek D., Ferrante R.J., Brown R.H., Julien J.P., Goldstein L.S., Cleveland D.W. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 2003, 302:113-117.
15. Cleveland D.W., Rothstein J.D. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci. 2001, 2:806-819.
16. DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., Kouri N., Wojtas A., Sengdy P., Hsiung G.Y., Karydas A., Seeley W.W., Josephs K.A., Coppola G., Geschwind D.H., Wszolek Z.K., Feldman H., Knopman D.S., Petersen R.C., Miller B.L., Dickson D.W., Boylan K.B., Graff-Radford N.R., Rademakers R. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011, 72:245-256.
17. Doyle J.P., Dougherty J.D., Heiman M., Schmidt E.F., Stevens T.R., Ma G., Bupp S., Shrestha P., Shah R.D., Doughty M.L., Gong S., Greengard P., Heintz N. Application of a translational profiling approach for the comparative analysis of CNS cell types. Cell 2008, 135:749-762.
18. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.X., et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994, 264:1772-1775.
19. Halassa M.M., Florian C., Fellin T., Munoz J.R., Lee S.Y., Abel T., Haydon P.G., Frank M.G. Astrocytic modulation of sleep homeostasis and cognitive consequences of sleep loss. Neuron 2009, 61:213-219.
20. Higashimori H., Morel L., Huth J., Lindemann L., Dulla C., Taylor A., Freeman M., Yang Y. Astroglial FMRP-dependent translational down-regulation of mGluR5 underlies glutamate transporter GLT1 dysregulation in the fragile X mouse. Hum. Mol. Genet. 2013, 22:2041-2054.
21. Ilieva H., Polymenidou M., Cleveland D.W. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 2009, 187:761-772.
22. Kang S.H., Li Y., Fukaya M., Lorenzini I., Cleveland D.W., Ostrow L.W., Rothstein J.D., Bergles D.E. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat. Neurosci. 2013, 16:571-579.
23. Kawamata H., Ng S.K., Diaz N., Burstein S., Morel L., Osgood A., Sider B., Higashimori H., Haydon P.G., Manfredi G., Yang Y. Abnormal intracellular calcium signaling and SNARE-dependent exocytosis contributes to SOD1G93A astrocyte-mediated toxicity in amyotrophic lateral sclerosis. J. Neurosci. 2014, 34:2331-2348.
24. Latini S., Pedata F. Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J. Neurochem. 2001, 79:463-484.
25. Ledent C., Vaugeois J.M., Schiffmann S.N., Pedrazzini T., El Yacoubi M., Vanderhaeghen J.J., Costentin J., Heath J.K., Vassart G., Parmentier M. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 1997, 388:674-678.
26. Lupica C.R., Proctor W.R., Dunwiddie T.V. Presynaptic inhibition of excitatory synaptic transmission by adenosine in rat hippocampus: analysis of unitary EPSP variance measured by whole-cell recording. J. Neurosci. 1992, 12:3753-3764.
27. Miyazaki N., Nakatsuka T., Takeda D., Nohda K., Inoue K., Yoshida M. Adenosine modulates excitatory synaptic transmission and suppresses neuronal death induced by ischaemia in rat spinal motoneurones. Pflugers Arch. 2008, 457:441-451.
28. Mojsilovic-Petrovic J., Jeong G.B., Crocker A., Arneja A., David S., Russell D.S., Kalb R.G. Protecting motor neurons from toxic insult by antagonism of adenosine A2a and Trk receptors. J. Neurosci. 2006, 26:9250-9263.
29. Morelli M., Carta A.R., Kachroo A., Schwarzschild M.A. Pathophysiological roles for purines: adenosine, caffeine and urate. Prog. Brain Res. 2010, 183:183-208.
30. Nam H.W., Bruner R.C., Choi D.S. Adenosine signaling in striatal circuits and alcohol use disorders. Mol. Cell 2013, 36:195-202.
31. Nascimento F., Pousinha P.A., Correia A.M., Gomes R., Sebastiao A.M., Ribeiro J.A. Adenosine A2A receptors activation facilitates neuromuscular transmission in the pre-symptomatic phase of the SOD1(G93A) ALS mice, but not in the symptomatic phase. PLoS One 2014, 9:e104081.
32. Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., McCluskey L.F., Miller B.L., Masliah E., Mackenzie I.R., Feldman H., Feiden W., Kretzschmar H.A., Trojanowski J.Q., Lee V.M. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314:130-133.
33. Potenza R.L., Armida M., Ferrante A., Pezzola A., Matteucci A., Puopolo M., Popoli P. Effects of chronic caffeine intake in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. Res. 2013, 91:585-592.
34. Renton A.E., Majounie E., Waite A., Simon-Sanchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., van Swieten J.C., Myllykangas L., Kalimo H., Paetau A., Abramzon Y., Remes A.M., Kaganovich A., Scholz S.W., Duckworth J., Ding J., Harmer D.W., Hernandez D.G., Johnson J.O., Mok K., Ryten M., Trabzuni D., Guerreiro R.J., Orrell R.W., Neal J., Murray A., Pearson J., Jansen I.E., Sondervan D., Seelaar H., Blake D., Young K., Halliwell N., Callister J.B., Toulson G., Richardson A., Gerhard A., Snowden J., Mann D., Neary D., Nalls M.A., Peuralinna T., Jansson L., Isoviita V.M., Kaivorinne A.L., Holtta-Vuori M., Ikonen E., Sulkava R., Benatar M., Wuu J., Chio A., Restagno G., Borghero G., Sabatelli M., Heckerman D., Rogaeva E., Zinman L., Rothstein J.D., Sendtner M., Drepper C., Eichler E.E., Alkan C., Abdullaev Z., Pack S.D., Dutra A., Pak E., Hardy J., Singleton A., Williams N.M., Heutink P., Pickering-Brown S., Morris H.R., Tienari P.J., Traynor B.J. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011, 72:257-268.
35. Renton A.E., Chio A., Traynor B.J. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 2014, 17:17-23.
36. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J.P., Deng H.X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62.
37. Sawynok J. Adenosine receptor activation and nociception. Eur. J. Pharmacol. 1998, 347:1-11.
38. Trussell L.O., Jackson M.B. Adenosine-activated potassium conductance in cultured striatal neurons. Proc. Natl. Acad. Sci. U. S. A. 1985, 82:4857-4861.
39. Vincenzi F., Corciulo C., Targa M., Casetta I., Gentile M., Granieri E., Borea P.A., Popoli P., Varani K. A2A adenosine receptors are up-regulated in lymphocytes from amyotrophic lateral sclerosis patients. Amyotroph. Lateral Scler Frontotemporal Degener. 2013, 14:406-413.
40. Xu K., Bastia E., Schwarzschild M. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. Pharmacol. Ther. 2005, 105:267-310.
41. Yamanaka K., Chun S.J., Boillee S., Fujimori-Tonou N., Yamashita H., Gutmann D.H., Takahashi R., Misawa H., Cleveland D.W. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat. Neurosci. 2008, 11:251-253.
42. Yang Y., Vidensky S., Jin L., Jie C., Lorenzini I., Frankl M., Rothstein J.D. Molecular comparison of GLT1+ and ALDH1L1+ astrocytes in vivo in astroglial reporter mice. Glia 2011, 59:200-207.
43. Yoshida Y., Une F., Utatsu Y., Nomoto M., Furukawa Y., Maruyama Y., Machigashira N., Matsuzaki T., Osame M. Adenosine and neopterin levels in cerebrospinal fluid of patients with neurological disorders. Intern. Med. 1999, 38:133-139.
44. Zhai J., Zhou W., Li J., Hayworth C.R., Zhang L., Misawa H., Klein R., Scherer S.S., Balice-Gordon R.J., Kalb R.G. The in vivo contribution of motor neuron TrkB receptors to mutant SOD1 motor neuron disease. Hum. Mol. Genet. 2011, 20:4116-4131.